Data / Form D filings / Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc.: Form D filings
Qualigen Therapeutics, Inc., a biotechnology company in Carlsbad, CA, filed 11 Form D notices with the SEC between 2009 and 2025. The latest, on August 13, 2025, reports $4.5 million sold of a $4.5 million offering to 14 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 5857 OWENS AVENUE, SUITE 300, Carlsbad, CA, 92008
- Phone
- (760) 452-8111
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1460702
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 13, 2025 | New notice | $4,500,000 | $4,500,000 | 14 | Jul 28, 2025 | sec.gov | |
| Nov 22, 2024 | New notice | $5,100,000 | $5,100,000 | 33 | Nov 18, 2024 | sec.gov | |
| Nov 9, 2018 | New notice | $6,000,000 | $6,000,000 | 11 | Nov 5, 2018 | sec.gov | |
| Dec 16, 2014 | New notice | $5,670,054 | $3,693,875 | $1,976,179 | 4 | Dec 4, 2014 | sec.gov |
| Nov 22, 2013 | Amendment | $7,366,914 | $7,366,914 | 16 | Nov 17, 2010 | sec.gov | |
| Aug 7, 2012 | Amendment | $6,800,000 | $5,801,545 | $998,455 | 14 | Nov 17, 2010 | sec.gov |
| Feb 23, 2012 | New notice | $3,500,000 | $526,445 | $2,973,555 | 1 | Feb 8, 2012 | sec.gov |
| Nov 30, 2010 | New notice | $5,000,000 | $1,950,527 | $3,049,473 | 8 | Nov 17, 2010 | sec.gov |
| Oct 12, 2010 | New notice | $250,000 | $250,000 | 2 | Sep 23, 2010 | sec.gov | |
| Mar 19, 2010 | New notice | $452,569 | $452,569 | 1 | Mar 4, 2010 | sec.gov | |
| Aug 17, 2009 | New notice | $1,000,000 | $1,000,000 | 1 | Aug 7, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Robert B. Lim | Director | |
| Braeden Lichti | Director | |
| Kevin Richardson II | Director | |
| Campbell Becher | Executive Officer, Director | |
| Cody B. Price | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Aug 11, 2025 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Qualigen Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.